Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092

Learn more:

• clinicaltrials.gov: #NCT04079738
• See Study Locations on Big Ten CRC Website